BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 31555580)

  • 1. Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer.
    Rice MA; Malhotra SV; Stoyanova T
    Front Oncol; 2019; 9():801. PubMed ID: 31555580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Androgen Receptor in Prostate Cancer: A Review.
    Fujita K; Nonomura N
    World J Mens Health; 2019 Sep; 37(3):288-295. PubMed ID: 30209899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
    Crawford ED; Schellhammer PF; McLeod DG; Moul JW; Higano CS; Shore N; Denis L; Iversen P; Eisenberger MA; Labrie F
    J Urol; 2018 Nov; 200(5):956-966. PubMed ID: 29730201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of hormonal directed pharmacotherapy for the treatment of prostate cancer.
    Mitsogianni M; Papatsoris A; Bala VM; Issa H; Moussa M; Mitsogiannis I
    Expert Opin Pharmacother; 2023; 24(16):1765-1774. PubMed ID: 37545430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms.
    Verma S; Prajapati KS; Kushwaha PP; Shuaib M; Kumar Singh A; Kumar S; Gupta S
    Cancer Drug Resist; 2020; 3(4):742-761. PubMed ID: 35582225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of Resistance to Second-Generation Antiandrogen Therapy for Prostate Cancer: Actual Knowledge and Perspectives.
    Pinto F; Dibitetto F; Ragonese M; Bassi P
    Med Sci (Basel); 2022 Apr; 10(2):. PubMed ID: 35645241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Darolutamide (ODM-201) for the treatment of prostate cancer.
    Shore ND
    Expert Opin Pharmacother; 2017 Jun; 18(9):945-952. PubMed ID: 28490267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational Second-Generation Antiandrogen Use in Prostate Cancer.
    Orme JJ; Pagliaro LC; Quevedo JF; Park SS; Costello BA
    Oncologist; 2022 Mar; 27(2):110-124. PubMed ID: 35641216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Darolutamide: A new drug for non-metastatic castration-resistant prostate cancer].
    Zhang F; Lu YP
    Zhonghua Nan Ke Xue; 2020 Apr; 26(4):364-368. PubMed ID: 33351306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer.
    Feng Q; He B
    Front Oncol; 2019; 9():858. PubMed ID: 31552182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
    Fizazi K; Smith MR; Tombal B
    Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal Therapy for Prostate Cancer.
    Desai K; McManus JM; Sharifi N
    Endocr Rev; 2021 May; 42(3):354-373. PubMed ID: 33480983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
    Chandrasekar T; Yang JC; Gao AC; Evans CP
    Transl Androl Urol; 2015 Jun; 4(3):365-80. PubMed ID: 26814148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy.
    Pham T; Sadowski MC; Li H; Richard DJ; d'Emden MC; Richard K
    Exp Hematol Oncol; 2015; 5():15. PubMed ID: 27340608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens.
    Ito Y; Sadar MD
    Res Rep Urol; 2018; 10():23-32. PubMed ID: 29497605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.
    Moilanen AM; Riikonen R; Oksala R; Ravanti L; Aho E; Wohlfahrt G; Nykänen PS; Törmäkangas OP; Palvimo JJ; Kallio PJ
    Sci Rep; 2015 Jul; 5():12007. PubMed ID: 26137992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.
    Imamura Y; Sadar MD
    Int J Urol; 2016 Aug; 23(8):654-65. PubMed ID: 27302572
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.